Maximizing survival in metastatic castrate-resistant prostate cancer: a clinical viewpoint

被引：0
|
作者：
Birtle, Alison [1 ]
机构：
[1] Royal Preston Hosp, Dept Oncol, Rosemere Canc Ctr, Preston PR2 9HT, Lancs, England
来源：
EXPERT REVIEW OF ANTICANCER THERAPY | 2013年 / 13卷 / 01期
关键词：
abiraterone; cabazitaxel; disease progression; docetaxel; metastatic castrate-resistant prostate cancer; survival; treatment sequencing; MITOXANTRONE PLUS PREDNISONE; CABAZITAXEL; MEN;
D O I：
10.1586/ERA.12.160
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Recently, licensed and emerging treatments for metastatic castrate-resistant prostate cancer are transforming the prognosis for men whose disease has already progressed during or after docetaxel-based chemotherapy. Two agents (cabazitaxel and abiraterone) are already accessible to prescribers, having shown survival benefits versus their comparators in randomized controlled trials, and other agents are showing promising results. A future in which metastatic castrate-resistant prostate cancer can be managed as a 'chronic disease' looks tantalizingly close. The challenge for clinicians will be to use these treatments rationally, in a way that optimizes each individual patient's chances of prolonged survival.
引用
收藏
页码：89 / 99
页数：11
相关论文
共 50 条
  • [21] Radioligand Therapy of Patients with Metastatic Castrate-Resistant Prostate Cancer
    E. R. Nemtsova
    A. A. Pankratov
    N. B. Morozova
    V. K. Tischenko
    V. M. Petriev
    V. V. Krylov
    P. V. Shegay
    S. A. Ivanov
    A. D. Kaprin
    [J]. Biology Bulletin, 2022, 49 : 2285 - 2297
  • [22] Oligoprogression in Metastatic, Castrate-Resistant Prostate Cancer-Prevalence and Current Clinical Practice
    Patel, Priyanka H.
    Tunariu, Nina
    Levine, Daniel S.
    de Bono, Johann S.
    Eeles, Rosalind A.
    Khoo, Vincent
    Murray, Julia
    Parker, Christopher C.
    Pathmanathan, Angela
    Reid, Alison
    van As, Nicholas
    Tree, Alison C.
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [23] Obesity is Associated with Longer Survival Independent of Sarcopenia and Myosteatosis in Metastatic and/or Castrate-Resistant Prostate Cancer
    Xu, Mark C.
    Huelster, Heather L.
    Hatcher, Jeremy B.
    Avulova, Svetlana
    Stocks, Blair T.
    Glaser, Zachary A.
    Moses, Kelvin A.
    Silver, Heidi J.
    [J]. JOURNAL OF UROLOGY, 2021, 205 (03): : 800 - 805
  • [24] Comorbidities predict overall survival (OS) in men with metastatic castrate-resistant prostate cancer (CRPC)
    Halabi, S.
    Kelly, W. K.
    George, D. J.
    Morris, M. J.
    Kaplan, E. B.
    Small, E. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [25] Survival and palliative care utilization among older veterans with metastatic castrate-resistant prostate cancer
    Pollock, Y. G.
    Fung, K.
    Shi, Y.
    Ngo, S.
    Walter, L. C.
    [J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2020, 68 : S245 - S245
  • [26] Castrate-Resistant Prostate Cancer Foreword
    Taneja, Samir S.
    [J]. UROLOGIC CLINICS OF NORTH AMERICA, 2012, 39 (04) : XIII - XIII
  • [27] Castrate-Resistant Prostate Cancer Preface
    Kibel, Adam S.
    [J]. UROLOGIC CLINICS OF NORTH AMERICA, 2012, 39 (04) : XV - XV
  • [28] Treatment of Castrate-Resistant Prostate Cancer
    Logothetis, Christopher J.
    [J]. JOURNAL OF UROLOGY, 2013, 190 (02): : 439 - 440
  • [29] Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer
    Zhang, Jingsong
    Cunningham, Jessica J.
    Brown, Joel S.
    Gatenby, Robert A.
    [J]. NATURE COMMUNICATIONS, 2017, 8
  • [30] Metastatic castrate-resistant prostate cancer: a discussion of the physical and psychosocial effects
    Flynn, Karen
    [J]. INTERNATIONAL JOURNAL OF UROLOGICAL NURSING, 2013, 7 (02) : 98 - 105
12345